Cusatuzumab is a high-affinity, anti-CD70 monoclonal antibody under investigation in acute myeloid leukemia (AML). This two-part, open-label, multicenter, phase I/II trial evaluated cusatuzumab plus azacitidine in patients with newly diagnosed AML ineligible for intensive chemotherapy. Patients received a single dose of cusatuzumab at one of four dose levels (1, 3, 10, or 20 mg/kg) 14 days before starting combination therapy. In phase I dose escalation, cusatuzumab was then administered on days 3 and 17, in combination with azacitidine (75 mg/m2) on days 1-7, every 28 days. The primary objective in phase I was to determine the recommended phase II dose (RP2D) of cusatuzumab plus azacitidine. The primary objective in phase II was efficacy at the RP2D (selected as 10 mg/kg). Thirty-eight patients were enrolled: 12 in phase I (three per dose level; four with European LeukemiaNet 2017 adverse risk) and 26 in phase II (21 with adverse risk). An objective response (≥partial remission) was achieved by 19/38 patients (including 8/26 in phase II); 14/38 achieved complete remission. Eleven patients (37.9%) achieved an objective response among the 29 patients in phase I and phase II treated at the RP2D. At a median follow-up of 10.9 months, median duration of first response was 4.5 months and median overall survival was 11.5 months. The most common treatment-emergent adverse events were infections (84.2%) and hematologic toxicities (78.9%). Seven patients (18.4%) reported infusion-related reactions, including two with grade 3 events. Thus, cusatuzumab/azacitidine appears generally well tolerated and shows preliminary efficacy in this setting. Investigation of cusatuzumab combined with current standard-of-care therapy, comprising venetoclax and azacitidine, is ongoing.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316251 | PMC |
http://dx.doi.org/10.3324/haematol.2022.281563 | DOI Listing |
J Diabetes Sci Technol
December 2024
Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia.
Introduction: Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.
View Article and Find Full Text PDFPhilos Trans A Math Phys Eng Sci
December 2024
Max-Planck-Institut für die Physik des Lichts, Erlangen 91058, Germany.
We derive a compact expression for the second-order correlation function [Formula: see text] of a quantum state in terms of its Wigner function, thereby establishing a direct link between [Formula: see text] and the state's shape in phase space. We conduct an experiment that simultaneously measures [Formula: see text] through direct photocounting and reconstructs the Wigner function via homodyne tomography. The results confirm our theoretical predictions.
View Article and Find Full Text PDFPhilos Trans A Math Phys Eng Sci
December 2024
School of Science, Centre for Quantum Dynamics, Griffith University, Nathan, Australia.
We place Loudon's quantum treatment of optical phase in in its historical context, and outline research that it inspired. We show how it led Pegg and Barnett to their quantum phase formalism, explaining the challenges that they overcame to define phase operators and phase eigenstates rigorously. We show how the formalism essentially constructs an extended rigged Hilbert space that supports strong limits of the phase operators and includes their eigenstates.
View Article and Find Full Text PDFPhilos Trans A Math Phys Eng Sci
December 2024
Institute of Optics, University of Rochester, Rochester, NY 14627, USA.
Can a quantum advantage for imaging resolution be realized with the help of quantum estimation theory? We expect so, but we show that, presently, theoretical tools are insufficiently developed to answer this question for extended objects. Still, there is much to be learned from the current state of the art. In this review, we re-examine prominent results in the literature and probe the limits of quantum metrology in addressing imaging resolution.
View Article and Find Full Text PDFPhilos Trans A Math Phys Eng Sci
December 2024
School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, UK.
It has been shown that measurements involving indefinite causal order can be superior to those in which a sequence of operations occurs in a specified order. In optics, such measurements are realized naturally in a Sagnac interferometer. We show that such an arrangement can measure the solid angle (on the Poincaré sphere) enclosed by a sequence of unitary transformations of the polarization.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!